Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Y. Samyshkin
PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With Kras Wild-Type Tumours in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Resource Use and Outcomes of Treatment of Community-Acquired Pneumonia in Russia: A Retrospective Field Study
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer
JAMA Oncology
Cancer Research
Oncology
Cetuximab in First Line Treatment of Metastatic Colorectal Cancer
Farmeconomia. Health economics and therapeutic pathways
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-Line Cetuximab and Irinotecan
JAMA Oncology
Cancer Research
Oncology
Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer
World Journal of Surgical Oncology
Surgery
Oncology
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation
OncoTargets and Therapy
Oncology
Pharmacology
The Cost–Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer (Mcrc) Who Have Progressed After Standard Therapies in Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
Cancers
Cancer Research
Oncology
